Revvity, Inc. on Friday announced a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile.
“Our fundamental goal for the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and ultimately, impact patient lives. In that vein, we are delighted to announce this non-exclusive agreement with AstraZeneca to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases,” Dr. Alan Fletcher, Senior Vice President, Life Sciences at Revvity, said in a statment.
According to the company, the Pin-point system and the underlying base editing technology is designed to enable highly efficient and precise single and multiplex (multi-gene) editing without an unintended impact on cell viability or functionality.
“Base editing has been demonstrated in T-cells and iPSCs using the Pin-point system, showing that the technology has potential across a range of cell types and therapeutic indications,” the company said in a statement.
Revvity has also developed a novel proprietary method to leverage the base editing mechanism to insert genes, such as to create an allogeneic CAR-T cell therapy by knocking in a CAR while knocking out immune markers simultaneously, it added.
